US Medicare issues updated rules for second round of drug negotiations

By Ahmed Aboulenein

WASHINGTON (Reuters) – The U.S. government will provide more time for negotiations and more chances for drugmakers to submit counter offers during the second round of talks over price cuts for its Medicare program, it said on Wednesday.

WHY IT’S IMPORTANT

The Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, the government health insurance program for millions of Americans age 65 and older and the disabled, by Feb. 1 will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.

The guidance is being closely watched by pharmaceutical manufacturers who make the 15 drugs likely to get picked for negotiations.

CMS said changes to the process, which came after feedback from patients and drugmakers, include meeting with companies earlier in the process and allowing more opportunities for counter offers.

The agency will now meet with drugmakers before making its initial offer, and will hold one of the three allotted negotiation meetings before the deadline for the first counter offer. If a company chooses to counter the government’s offer, it will have two further meetings to negotiate.

KEY QUOTES

“What we plan to do is have meetings with manufacturers before CMS actually sends an initial offer. But then once we have done an initial offer, we will have a first optional negotiation meeting with the manufacturer earlier than we did this past year,” a CMS official told reporters on a press call.

“That will provide us with an opportunity to have a dialogue about the initial offer that CMS has sent, and potentially some early thinking from the manufacturer themselves around how they might do a counteroffer.”

CONTEXT

CMS announced prices for ten drugs in August in its first round of cuts following a year of talks. The prices are set to take effect in January 2026 and will save older Americans $1.5 billion in out of pocket costs, according to the agency.

Next year’s talks will take place in a shorter timeframe, with a final decision on prices due by Nov. 30, 2025.

(Reporting by Ahmed Aboulenein; Editing by Sonali Paul)

More From Author

Fed’s Goolsbee says dockworkers’ strike could lead to higher prices

California investigating possible human case of bird flu, state says

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Ad  RAD Intel

The Company Fixing Ads Isn't Public Yet-But Insiders Are Investing

You've seen them. The cringey, mistargeted, and downright WTF ads. You sit there wondering why brands are spending billions on content that just leaves you questioning your entire algorithmic existence after seeing it.

RAD Intel is teaching brands - with proprietary tech - how to read the room. Their AI helps brands understand why content works, who it actually resonates with, and what to say next. RAD analyzes real-time audience behavior and predicts what will convert, so brands can stop guessing and start making ads that actually land.

And it's already in serious demand. Fortune 1000 brands like Hasbro, Sweetgreen, Skechers, and MGM are using RAD Intel to level up their marketing - and getting up to 3.5x better results. With $37M+ raised and a valuation that's jumped from $5M to $85M*, it's a bit of a shock that RAD Intel is still pre-IPO. Shares are just $0.60, and investors from Meta, Google, Amazon, and Fidelity Ventures are already in.

So check them out now and get in on the action before then, lest you get stuck in the "I almost invested" cycle of regret.

Invest by May 8, before it's too late.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering. Please read the offering circular and related risks at invest.radintel.ai.

Subscribe to our free Newsletter!



Recent Comments

No comments to show.

Categories